• By Donald Zuhn –-

    USPTO SealIn an interesting decision issued last year, the Patent Trial and Appeal Board reversed the final rejection of claims 1-5 and 9 in U.S. Application No. 12/959,017.  The claims at issue had been rejected under 35 U.S.C. § 101 as reciting patent ineligible subject matter in the form of an abstract idea, and under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 6,454,707 and U.S. Patent Application Publication Nos. US 2006/0226079 A1 and US 2009/0082684 A1.  This post addresses the Board's reversal of the § 101 rejection.

    The '017 application relates to the identification of a patient undergoing hemodialysis treatments at increased risk for death.  Representative claim 1 recites:

    1.  A method of identifying and treating a patient undergoing periodic hemodialysis treatments at increased risk for death, comprising:
        a) determining at least one clinical or biochemical parameter associated with an increased risk of death of the patient and monitoring said parameter periodically before and/or after the patient is undergoing hemodialysis treatments;
        b) determining a significant change in the rate of change of the at least one clinical or biochemical parameter from a retrospective record review of parameter values of the patient determined at prior hemodialysis treatments;
        c) identifying the patient as having an increased risk for death because the patient has the significant change in the rate of change of the at least one clinical or biochemical parameter; and
        d) treating the patient having an increased risk for death within a sufficient lead time to decrease the patient's risk of death.

    In reversing the § 101 rejection, the Board began by noting that it was "persuaded by Appellants' arguments that the claimed method is not an abstract idea, because the claims 'have the particular practical application of identifying a patient as having an increased risk of death and treating the patient to decrease the risk of death.'"  The Board also noted that the Examiner's rejection of claim 1 was based on the finding that steps a) to c) can be performed with mental thought alone, and that treating step d) is not a "transformation of a patient" because "the treatment step can be anything; i.e. not necessarily having to do with hemodialysis."  In the Examiner's Answer, the Examiner concluded that "the claim is effectively [directed] to the general correlation and the abstract idea of doing the significant change analysis."

    The Board, however, disagreed with the Examiner, stating that:

    Although the claim includes steps that can be performed mentally, "treating the patient . . . to decrease the patient's risk of death" is not a phenomenon of nature, mental process, or abstract intellectual concept.  This is a specific type of treatment, as opposed to, for example, treating only to alleviate pain.  The claim as a whole is directed to more than just steps capable of being performed mentally.

    The Board explained that "the claim, considered as a whole, is not directed merely to an abstract idea, as defined under step one of the Alice analysis, because it includes treating a patient to reduce a risk of death."  Citing Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 134 S. Ct. 2347, 2359 (2014), the Board also suggested that "if one were to consider the claim under the second step of the Alice analysis, the treatment of a patient to reduce the risk of death functions to 'effect an improvement in [another] technology or technical field,' namely medicine."

    The Board therefore refused to sustain the rejection of claim 1 (or dependent claims 2-5 and 9) under § 101.  After also refusing to sustain the rejection of claims 1-5 and 9 under § 103, the Board reversed the rejection of claims 1-5 and 9 under §§ 101 and 103.

    Following the Board's Decision on Appeal on March 20, 2017, a Notice of Allowance was mailed on June 8, 2017.  A Request for Continued Examination and Information Disclosure Statement was filed on August 31, 2017, and a second Notice of Allowance was mailed on September 20, 2017.  The '017 application issued as U.S. Patent No. 9,883,799 on February 6, 2018.

    Ex parte Kotanko (PTAB 2018)
    Panel: Administrative Patent Judges Crawford, Fischetti, and Kim
    Decision on Appeal by Administrative Patent Judge Crawford

  • By Donald Zuhn –-

    ActelionLast week, the Federal Circuit affirmed the grant of summary judgment by the District Court for the Eastern District of Virginia in favor of the U.S. Patent and Trademark Office with respect to the USPTO's determination of Patent Term Adjustment ("PTA") for U.S. Patent No. 8,658,675.  In particular, the Federal Circuit determined that the District Court did not err in affirming the USPTO's finding that Actelion failed to make an express request for early examination of the '619 application, as required by 35 U.S.C. § 371(f), and that the District Court also did not err in affirming the USPTO's A Delay calculation for the '675 patent, which was based on national stage commencement occurring on the day after a federal holiday.

    The '675 patent, which is directed to pyridin-4-yl derivatives that are agonists for the G protein-coupled receptor S1P1/EDG1, is assigned to Actelion Pharmaceuticals, Ltd.  The '675 patent issued from U.S. Application No. 13/383,619, which was filed on January 12, 2012 as a national stage application from International Application No. PCT/IB2010/053224, which claims priority from International Application No. PCT/IB2009/053089, which was filed on July 16, 2009.  The 30-month date for national stage entry of International Application No. PCT/IB2010/053224 was therefore January 16, 2012, which fell on Martin Luther King, Jr. Day, a federal holiday.

    When the '619 application was filed, Actelion also filed a preliminary amendment, which stated that "Applicant earnestly solicits early examination and allowance of these claims."  In addition, Actelion filed a PTO Form 1390 ("Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission under 35 U.S.C. 371") when filing the '619 application, but did not check the box indicating that "[t]his is an express request to begin national examination procedures (35 U.S.C. [§] 371(f)). . . ."  The USPTO thereafter issued a restriction requirement on April 26, 2013.

    An Issue Notification was subsequently issued for the '675 patent, which included a PTA determination of 41 days.  Actelion filed a request for reconsideration of PTA in view of the AIA Technical Corrections Act, and the USPTO responded by reducing the PTA for the '675 patent to 40 days.  Actelion then filed a petition for reconsideration, contending that the '675 patent was entitled to 45 days of PTA based on its January 12, 2012 filing date, or alternatively, 41 days based on the 30-month date of January 16, 2012.  The USPTO denied Actelion's petition, Actelion filed a second petition for reconsideration, and then Actelion filed suit against the USPTO in the Eastern District of Virginia pursuant to 35 U.S.C. § 154(b)(4).

    Before the District Court, Actelion filed a motion for summary judgment and the USPTO filed a cross-motion for summary judgment.  The District Court granted summary judgment in favor of the USPTO, finding that Actelion had failed to meet the conditions under 35 U.S.C. § 371(b) and (f) on the day the '619 application was filed, and that the USPTO had properly determined that the national stage did not commence on the 30-month date that fell on a federal holiday.  Actelion appealed to the Federal Circuit.

    The Federal Circuit began by noting that the only dispute in this case was the A Delay calculation under 35 U.S.C. § 154(b)(1)(A)(i)(II) for the '675 patent, which issued from the '619 application, which was filed as a national stage application pursuant to 35 U.S.C. § 371.  The Court also noted that under the current version of § 154(b)(1)(A)(i)(II), which was amended pursuant to the Technical Corrections—Leahy-Smith America Invents Act ("Technical Corrections Act" or "TCA"), the USPTO was required to "provide at least one of the notifications under section 132 or a notice of allowance under section 151 not later than 14 months after . . . the date of commencement of the national stage under section 371 in an international application."  Prior to enactment of the TCA, § 154(b)(1)(A)(i)(II) required that the USPTO provide such notification not later than 14 months after "the date on which an international application fulfilled the requirements of section 371 of this title."  The Court further noted that the commencement of national stage of an international patent application is specified in 35 U.S.C. § 371, which provides in § 371(b) that "[s]ubject to subsection (f) of this section, the national stage shall commence with the expiration of the applicable time limit under article 22(1) or (2), or under article 39(1)(a) of the treaty"; provides applicant filing requirements in § 371(c); and provides in § 371(f) that "[a]t the express request of the applicant, the national stage of processing may be commenced at any time at which the application is in order for such purpose and the applicable requirements of subsection (c) of this section have been complied with."

    On appeal, Actelion argued that the A Delay calculation for the '675 patent should be based on the '619 application's filing date because Actelion "fulfilled the requirements of section 371" by fulfilling the applicant filing requirements of § 371(c).  Actelion also argued that it made an "express request" as required by § 371(f), despite not checking the box on PTO Form 1390, by stating in its preliminary amendment that it "earnestly solicits early examination."  Actelion further argued that even if the A Delay calculation for the '675 patent was not based on the '619 application's filing date, the A Delay calculation should be based on the 30-month date without regard to the fact that the 30-month date fell on a federal holiday.  Actelion based this last argument on § 371(b), which requires that the national stage "shall commence" on the expiration of the date that is 30 months from the priority date.  In affirming the District Court's grant of summary judgment to the USPTO, the Federal Circuit disagreed with all three of Actelion's arguments above.

    With regard to Actelion's first argument, the Court determined that § 154(b)(1)(A)(i)(II) — regardless of whether the pre- or post-TCA version is considered — requires compliance with the entirety of § 371, which includes the requirements under § 371(b) and (f).  With regard to Actelion's second argument that the preliminary amendment filed by Actelion with the '619 application contained an "express request" to commence national stage early (as required by § 371(f)), the Federal Circuit called such argument "unsound," explaining that:

    Even viewed most favorably to Actelion, the casual "solicits early examination" language with no reference to § 371(f), the PCT, or the national stage, when combined with the unchecked box 3 of its completed PTO Form 1390, was, if not an express election not to commence the national stage early, at least an inconsistent or ambivalent request.

    Finally, the Federal Circuit found Actelion's third argument to be unpersuasive, noting that Actelion's argument "is premised on the assumption that any time period of inaction that is not attributable to the applicant should inure to the applicant's benefit," and "[a]s such, Actelion emphasizes its alleged lack of fault during the time periods in question" (emphasis in opinion).  The Court, however, responded that:

    [B]y the same logic, inaction on a holiday is also not attributable to the PTO.  Although the PTA statutes do serve a remedial purpose of restoring patent term lost during prosecution of an application, they only restore "undue delays in patent examination caused by the PTO" as provided by Congress [emphasis in opinion].

    The Federal Circuit therefore concluded that the USPTO did not err in calculating a 40-day PTA for the '675 patent under § 154(b)(1)(A)(i)(II), and affirmed the District Court's decision granting summary judgment in favor of the USPTO.

    Actelion Pharmaceuticals, Ltd. v. Matal (Fed. Cir. 2018)
    Panel: Circuit Judges Lourie, O'Malley, and Wallach
    Opinion by Circuit Judge Lourie

  • CalendarFebruary 13, 2018 – "Patent Drafting for Machine Learning: Structural Claim Limitations, Avoiding §101 or §112 Rejections" (Strafford) – 1:00 to 2:30 pm (EST)

    February 13, 2018 - "eMod Update: Patent Center and Structured Text" (U.S. Patent and Trademark Office) – 12:00 to 1:00 pm (ET)

    February 14, 2018 – "Sect. 112 Indefiniteness in Chemical and Biotech Patent Claims — Drafting and Prosecuting Patent Claims That Will Hold Up Under Any Definiteness Standard" (Strafford) – 1:00 to 2:30 pm (EST)

    February 14, 2018 – "Tech Transfer for Medical Advances: Challenges and Opportunities in Commercializing Academic Biomedical Research" (Keystone Symposia on Molecular and Cellular Biology) – 12:00 to 1:30 pm (ET) on 

    February 17, 2018 – "Patent Post-Grant Practice" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – 9:00 am to 4:30 pm, Chicago, IL

    February 20, 2018 – "Patent-Eligibility in 2018: Current Status and Best Practices" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    February 21-22, 2018 – Advanced Summit on Life Sciences Patents (American Conference Institute) – New York, NY

    February 22, 2018 – "Managing Patent Infringement Risk in Product Development" (Strafford) – 1:00 to 2:30 pm (EST)

    February 26, 2018 – "Chinese Patent Developments" (Practising Law Institute) – 4:00 to 5:00 pm (Eastern)

    March 3, 2018 – "Patent Post-Grant Practice" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – 9:00 am to 4:30 pm, Chicago, IL

    March 5-6, 2018 – Advanced Patent Law Seminar (Chisum Patent Academy) – Houston, TX

    March 8-9, 2018 – Advanced Patent Law Seminar (Chisum Patent Academy) – Cincinnati, OH

    March 14, 2018 – Patent Litigation Seminar (New Jersey Intellectual Property Law Association) – 12:00 to 5:00 pm, Iselin, NJ

  • NJIPLAThe New Jersey Intellectual Property Law Association (NJIPLA) will be holding a Patent Litigation Seminar from 12:00 to 5:00 pm on March 14, 2018 in Iselin, NJ.  The seminar will offer presentations on the following topics:

    • Life Technologies Corp. v. Promega Corp.
    • Impression Products, Inc. v. Lexmark International, Inc.
    • Oil States Energy Services, LLC v. Greene's Energy Group, LLC
    •
    The Inequitable Conduct Doctrine: A Look Back and Forward (ethics session)
    • Litigating Written Description

    Additional information regarding the seminar, including a complete agenda and list of speakers, can be found here.  The registration fee for the seminar is $225 (general), $125 (corporate/government employee), or $50 (students).  Those interested in registering for the seminar can do so here.

  • PLI #1Practising Law Institute (PLI) will be offering a one-hour webcast on "Chinese Patent Developments" on February 26, 2018 beginning at 4:00 pm (Eastern).  Elizabeth Chien-Hale of the Institute for Intellectual Property in Asia will discuss the latest and future changes planned by China's State Intellectual Property Office, both structurally (local IP bureaus, satellite offices) and legally (changes to Patent Examination Guidelines and the Patent Law). Attendees will also receive point‑by‑point comparisons between several areas of patent law that were much discussed in the U.S. system in recent years, and their counterparts in the Chinese system.  The webcast will use examples and cases to illustrate the changes in Chinese patent system in the following three areas:

    • Quality and Scope: accelerated examination, expanded protection for software and business method patents, and proposed changes to the Fourth Amendments to the Patent Law;
    • Protection: increasing efforts on administrative enforcement, reducing burden on evidence collection, increasing damage awards; and
    • Commercialization: innovation-based entrepreneurship.

    The registration fee for this webcast is $299.  Those interested in registering for the webcast, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Managing Patent Infringement Risk in Product Development" on February 22, 2018 from 1:00 to 2:30 pm (EST).  Gregory M. Ansems, Assistant General Counsel, Intellectual Property, Honeywell International; Thomas Hipkins of Fredrikson & Byron; and Jeffrey C. Totten of Finnegan Henderson Farabow Garrett & Dunner will provide guidance to patent counsel on identifying and addressing patent infringement risk in the product development process. The panel will examine how the courts have applied Halo and offer strategies for minimizing patent infringement risk.  The webinar will review the following issues:

    • What are best practices for patent counsel when analyzing infringement risk issues in the product development process?
    • When should counsel seek opinions to protect new research and products from infringement claims?
    • How are courts ruling on enhanced damages since the Halo decision?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • JMLSThe John Marshall Law School Center for Intellectual Property, Information & Privacy Law will be hosting Russell Cass of Clark Hill PLC, who will be presenting a CLE course entitled "Patent Post-Grant Practice" from 9:00 am to 4:30 pm on February 17, 2018 and March 3, 2018 at the John Marshall Law School in Chicago, IL.  The course will review the purpose and history of post-grant proceedings (i.e., Inter Partes Reviews (IPRs), Post-Grant Review (PGRs), and Covered Business Method Proceedings (CBMs)), the statutory framework, and how these proceedings fit into the overall patent landscape.  The course will then cover the various phases of the proceedings, including the petition, response and reply, discovery, evidentiary issues, use of experts, oral hearing, and appeal to the Federal Circuit.  The interplay between PTAB contested proceedings and district court litigation will also be explored.

    Tuition for the course is $1,565.  Those interested in registering for the conference can do so here.

  • Keystone SymposiaKeystone Symposia on Molecular and Cellular Biology will be offering a virtual symposium entitled "Tech Transfer for Medical Advances: Challenges and Opportunities in Commercializing Academic Biomedical Research" on from 12:00 to 1:30 pm (ET) on February 14, 2018.  Juan Carlos López of Haystack Science will moderate a panel consisting of Lita Nelsen, former Director of the MIT Technology Licensing Office; Curtis Keith of Harvard University; Katherine Bowdish of Sunrise Ventures Sanofi; and Avi D. Spier of Novartis Institutes of Biomedical Research.  The panel will discuss issues such as the key considerations when deciding what project to commercialize, how academic institutions can learn more about what investors or pharma look for when they scout for projects. what the biggest obstacles are for investors when interacting with academic institutions, and other related questions.

    Additional information about the symposium can be found here.  Those interested in registering for the symposium can do so here.  To determine whether your system is compatible, a system checker can be accessed here.

  • By Michael Borella —

    Federal Circuit SealThis first five or so weeks of 2018 have been busy for Federal Circuit 35 U.S.C. § 101 jurisprudence.  At last count, four substantive decisions have come down so far (including this one, but not including Rule 36 judgments without opinion).  Out of these, two have found the claims at issue to be patent-eligible, and one has found the claims to be ineligible.  This case splits the baby, finding some claims ineligible and others in need of further review.

    But the impact of today's decision may be further-reaching than the other three.  At the very least, it provides a degree of clarity as to the evidentiary standard applicable to a § 101 challenge on summary judgment.  This may result in the USPTO having to update its § 101 guidance for examiners and the PTAB.

    Steven E. Berkheimer brought an action against HP in the Northern District of Illinois, alleging infringement of U.S. Patent No. 7,447,713.  After a Markman hearing in which the judge construed several claim terms, HP moved for summary judgment under § 101.  The District Court granted the motion and Berkheimer appealed.

    The '713 patent is directed to "digitally processing and archiving files in a digital asset management system."  This system "parses files into multiple objects and tags the objects to create relationships between them," then compares these objects to "to archived objects to determine whether variations exist based on predetermined standards and rules."  Doing so "eliminates redundant storage of common text and graphical elements, which improves system operating efficiency and reduces storage costs."

    Claims 1 and 4 of the '713 patent recite:

    1.  A method of archiving an item comprising in a computer processing system:
        presenting the item to a parser;
        parsing the item into a plurality of multi-part object structures wherein portions of the structures have searchable information tags associated therewith;
        evaluating the object structures in accordance with object structures previously stored in an archive;
        presenting an evaluated object structure for manual reconciliation at least where there is a predetermined variance between the object and at least one of a predetermined standard and a user defined rule.

    4.  The method as in claim 1 which includes storing a reconciled object structure in the archive without substantial redundancy.

    The Supreme Court's Alice Corp. v. CLS Bank Int'l case set forth a two-part test to determine whether claims are directed to patent-eligible subject matter under § 101.  One must first decide whether the claim at hand is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further decide whether any element or combination of elements in the claim is sufficient to ensure that the claim amounts to significantly more than the judicial exclusion.  But generic computer implementation of an otherwise abstract process does not qualify as "significantly more."  On the other hand, a claimed improvement to a computer or technological process is typically patent-eligible.

    The Federal Circuit began by addressing whether Berkheimer waived his ability to separately argue for the eligibility of the independent and dependent claims.  Notably, a court will usually conduct a § 101 analysis only on a small number of claims (e.g., one) for purpose of judicial economy.  According to the Federal Circuit, "[c]ourts may treat a claim as representative in certain situations, such as if the patentee does not present any meaningful argument for the distinctive significance of any claim limitations not found in the representative claim or if the parties agree to treat a claim as representative."

    HP asserted that claim 1 was representative.  But Berkheimer never agreed to this notion, and in fact separately argued claim 5 in an opposition to HP's summary judgment motion.  In the opposition, Berkheimer also argued for the eligibility of other features that only appear in claims 4-7.  The Court observed that an independent claim is not automatically a representative claim just because it is independent.  Also, since Berkheimer "advanced meaningful arguments regarding limitations found only in the dependent claims," these separate arguments were not waived.

    Turning to part one of the § 101 analysis, the District Court had ruled that claim 1 was directed to "the abstract idea of 'using a generic computer to collect, organize, compare, and present data for reconciliation prior to archiving.'"  Addressing the claims separately, the Federal Circuit held that "claims 1-3 and 9 are directed to the abstract idea of parsing and comparing data; claim 4 is directed to the abstract idea of parsing, comparing, and storing data; and claims 5-7 are directed to the abstract idea of parsing, comparing, storing, and editing data."

    To justify this position, the Court found analogies between Berkheimer's claims and those of In re TLI Commc'ns LLC Patent Litig. and Content Extraction & Transmission LLC v. Wells Fargo Bank, Nat'l Ass'n.  In both of those prior cases, claims directed to obtaining, processing, and storing data were found to be abstract.  Berkheimer argued that the claims were not abstract because "the 'parsing' limitation roots the claims in technology and transforms the data structure from source code to object code."  But the Court rejected this notion, stating "[t]hat the parser transforms data from source to object code does not demonstrate non-abstractness without evidence that this transformation improves computer functionality in some way."  In support, the Court pointed out that Berkheimer had admitted that parsers existed well before the priority date of the '713 patent.

    Then the Court turned to step two of the § 101 inquiry.  This is where things get interesting.

    The Court reiterated that "[t]he second step of the Alice test is satisfied when the claim limitations involve more than performance of well-understood, routine, and conventional activities previously known to the industry."  The Court went on to flesh out this concept:

    The question of whether a claim element or combination of elements is well-understood, routine and conventional to a skilled artisan in the relevant field is a question of fact.  Any fact, such as this one, that is pertinent to the invalidity conclusion must be proven by clear and convincing evidence.  Like indefiniteness, enablement, or obviousness, whether a claim recites patent eligible subject matter is a question of law which may contain underlying facts [emphasis added].

    In support of this statement, the Court cited to similar language in its Accenture Global Servs., GmbH v. Guidewire Software, Inc. case, as well as Justice Breyer's statement from Mayo v. Prometheus that the § 101 inquiry may overlap with fact-sensitive inquiries such as novelty under § 102.

    Nonetheless, some § 101 disputes may be resolved as a matter of law when there is no material issue of fact regarding whether one or more claim elements or combination thereof is well-understood, routine, or conventional to a person of ordinary skill in the art.  In this case, however, Berkheimer argued that "summary judgment is improper because whether the claimed invention is well-understood, routine, and conventional is an underlying fact question for which HP offered no evidence."

    The Court went on:

    While patent eligibility is ultimately a question of law, the district court erred in concluding there are no underlying factual questions to the § 101 inquiry.  Whether something is well-understood, routine, and conventional to a skilled artisan at the time of the patent is a factual determination.  Whether a particular technology is well-understood, routine, and conventional goes beyond what was simply known in the prior art.  The mere fact that something is disclosed in a piece of prior art, for example, does not mean it was well-understood, routine, and conventional.

    Thus, the Court is distinguishing between whether a technology is "known" in the sense of § 102 (e.g., publically available) and whether one of ordinary skill would find this technology to be well-understood, routine, and conventional (e.g., something that this person of ordinary skill would consider to be textbook knowledge or part of his or her ordinary course of activities).

    The specification of the '713 patent states that, at the time of the invention, existing digital asset management systems included "numerous documents containing multiple instances of redundant document elements" which resulted in "inefficiencies and increased costs."  The specification continued on to explain that the claimed invention "increases efficiency and computer functionality over the prior art systems."  Thus, according to the Court, "[t]he improvements in the specification, to the extent they are captured in the claims, create a factual dispute regarding whether the invention describes well-understood, routine, and conventional activities, so we must analyze the asserted claims and determine whether they capture these improvements."

    Ultimately, the Court concluded that claim 1 does not provide an inventive concept beyond that of the abstract idea therein.  Particularly, claim 1 "does not include limitations which incorporate eliminating redundancy of stored object structures or effecting a one-to-many change of linked documents within an archive."  Furthermore, claim 1 "does not even require the storage of data after it is presented for manual reconciliation."  On the other hand, claim 4 and claims 5-7 that depend therefrom recite "limitations directed to the arguably unconventional inventive concept described in the specification [, that] storing object structures in the archive without substantial redundancy improves system operating efficiency and reduces storage costs."

    Accordingly, the Court concluded that "there is at least a genuine issue of material fact in light of the specification regarding whether claims 4-7 archive documents in an inventive manner that improves these aspects of the disclosed archival system."  Thus, "[w]hether claims 4-7 perform well-understood, routine, and conventional activities to a skilled artisan is a genuine issue of material fact making summary judgment inappropriate with respect to these claims."  This does not mean that claims 4-7 are patent-eligible, only that the District Court's summary judgment ruling was improper for these claims.  So, the case was remanded back to that court to make such a determination.

    This holding and the supportive reasoning appears to be the first time that the Federal Circuit has explicitly required that a district court make findings of fact in order to justify a § 101 decision.  Previously, § 101 determinations have been addressed purely as a matter of law.  Nonetheless, many such decisions compared the claimed subject matter to prior art, and even used the term "prior art" when doing so.

    Since Alice, a challenger has been able to make conclusory statements that claim elements are well-understood, routine, and conventional.  When a patentee would rebut these statements as unsupported, a court could rule that, as a matter of law, there was no need for the challenger to provide supporting evidence.  Similarly, in the USPTO, examiners routinely make § 101 rejections that are conclusory in a similar fashion, and decline to consider evidence to the contrary.

    Has this case changed § 101 procedures to the point where patentee or applicant has an opportunity to rebut such presumptive techniques?  With the requirement that the challenger provide clear and convincing evidence of ineligibility, it seems so.  If nothing else, it is now apparent that facts matter in the § 101 analysis.  This may make it more difficult to invalidate patents on the pleadings, as well as at the summary judgment stage.

    Berkheimer v. HP Inc. (Fed. Cir. 2018)
    Panel: Circuit Judges Moore, Taranto, and Stoll
    Opinion by Circuit Judge Moore

  • U.S. Government Fails in Attempt to Invalidate U.S. Patents under § 101

    By Joseph Herndon —

    In a bit of an ironic outcome, the U.S. government was unsuccessful in invalidating U.S. patents under § 101.  It seems odd that the government issued the patents on the one hand, and later, tried to invalidate them.

    Plaintiff, Science Applications International Corp. ("SAIC"), claimed that the U.S. government infringed four patents by entering into contracts with plaintiff's competitors for the procurement of specialized heads up displays ("HUD") and night vision goggles that allegedly use SAIC's patented technology.  Defendant, the United States, moved to dismiss for failure to state a claim under Rule 12(b)(6), contending that Plaintiff's patents claim ineligible subject matter under 35 U.S.C. § 101.

    The patents at issue here are U.S. Patent Nos. 7,787,012; 8,817,103; 9,229,230; and 9,618,752.  The four patents form two patent families due to the interrelatedness of the applications.

    The first patent family (the '012 and '103 Patents) are directed to video image registration in a HUD.  The '012 Patent describes methods for displaying images on a HUD.  The '012 Patent describes that the prior art placed one image on top of another, using a beam combiner, but it could not dynamically compare, adjust, or reposition an image using orientation data such that the narrower field of vision was displayed accurately in the transparent display.  The prior technique superimposed by simply placing the narrower field of vision within the broader field of vision.  Although a user could view both fields, the user ran the risk of mismatched boundaries, repetitive or obscure images, and the inability to recalculate with movement.  The patent claims purport to solve these problems in the process of registering two independently moveable fields of vision.  Claim 1 of the '012 Patent is set forth below.

    1.  A method of registering video images with an underlying visual field comprising the steps of:
        (1) determining a source orientation of a video source providing a video feed containing data for a series of video images representing portions of a visual field;
        (2) determining a display orientation of a transparent display overlaying the visual field, wherein the video source and the transparent display are independently movable about multiple axes; and
        (3) displaying the video images in positions on the transparent display that overlay portions of the visual field represented by the displayed video images,
        wherein boundaries of the displayed video images are in registration with boundaries of portions of the visual field represented by the displayed video images.

    The '103 Patent is a division of the '012 Patent and has corresponding system claims.

    The second patent family (the '230 and '752 Patents) is directed to video image registration and providing supplemental data in a HUD.

    The '230 Patent describes that the identification and comparison system dynamically places images within the transparent display such that matching images appear despite movement of either the display or the second video source and without obscuring relevant portions of the scene with mismatched images.  The '230 Patent purports to offer an advance over the requirement for manual recalibration found in prior approaches.  The patent claims minimize the manual recalibration by using the location comparison data to adjust how subsequent sensor-based locations are determined.  The claims thus build on the previous techniques for superimposition by increasing accuracy and decreasing the need for manual adjustments.  Claim 15 of the '230 Patent is set forth below.

    15.  A method, comprising:
        (a) receiving video images from a first video source and from a second video source representing portions of an external environment;
        (b) receiving motion data indicative of motion of the first and second video sources;
        (c) identifying, based on the received motion data, a part of a first video source image that potentially represents a portion of the external environment represented in a part of a second video source image;
        (d) evaluating, based on a comparison of data from the first and second video source images, the identification performed in step(c); and
        (e) displaying at least a portion of the first video source image and at least a portion of the second video source image such that the second video source image portion overlays a corresponding region of the first video source image portion, wherein the corresponding region represents a portion of the external environment represented in the second video source portion.

    The '752 Patent is a continuation of the '230 Patent and has claims of generally the same scope.

    The Court followed the two-part Alice/Mayo test for determining whether a patent claims ineligible subject matter.  First, a court must determine whether the patent is directed to a patent-ineligible concept, such as an abstract idea.  If so, the second step is to determine, considering the claims both individually and as an ordered combination, whether the patent claims sufficiently transform the ineligible subject matter with an inventive concept.

    The government's arguments regarding the first and second patent family can be set out together.  The government contended that SAIC's patents claim the abstract idea of superimposing a video image in a location on a display, thereby preempting future innovation in how images can be manipulated to appear in the same field of vision.

    SAIC responded that none of the claims are directed to the underlying idea of superimposing images.  Rather, SAIC contended that its patents focus on solving a problem in the technology available for registering images by combining orientation sensors and data, inertial sensors and motion data, boundary registration, and independently movable components.

    The Court noted that, at a high level, all four claims undoubtedly involve the idea of superimposition of images.  But the Federal Circuit has admonished that just because the claims involve an abstract idea does not mean that they are directed to an abstract idea.  The Court framed the question as whether the claims are directed to the idea of superimposing one image on another or whether the claims "recite more than a mere result."

    The Court gave heavy weight to the claims being similar to patent claims previously found to satisfy § 101 in Thales Visionix, in which claims offered an improvement to accuracy when "measuring relative position and orientation of a moving object on a moving reference frame."  Using a comparative analysis, it seems for this reason alone, the Court found the patent claims at issue here to also satisfy § 101.

    In addition, the Court found that the '012 method claim and the '103 system claim are directed to improving prior processes by using known components in an unconventional way to register images within accurate boundaries.  The Court also found that the '752 and '230 method claims further describe how to combine known components, including inertial sensors, to communicate motion data such that the images can be accurately aligned and the calibration process can be tied to the collected location data.  The claims, therefore, recited more than a mere result by including details for carrying out the claimed invention.

    The Court strictly followed the Alice/Mayo test for section 101, and noted that this test is not concerned with whether an artisan skilled in the art can perform the method claimed by the patent nor whether the claim language is sufficiently definite, novel, or non-obvious, but rather whether the character of a claim as a whole is directed to a patent-ineligible subject matter.  Taken on the face of the claims and the specification, the Court found that SAIC's patents combine existing computer technology, sensors, and calculations in an unconventional way in order to reach a solution to the problem of alignment and consistently accurate display.  Because SAIC did not stop at the concept of superimposition (in the abstract) but instead provided a solution for achieving accuracy and consistency in image registration, SAIC's claims are not directed to an abstract idea.

    The Court thus denied defendant's motion to dismiss for failure to state a claim pursuant to Rule 12(b)(6) since the claims satisfied step 1 of the Alice/Mayo test (and therefore, it was unnecessary to progress to Alice/Mayo step 2).

    Science Application International Corp. v. United States (Fed. Cl. 2018)
    Order by Senior Judge Eric G. Bruggink